ACTRN12624000204549RecruitingPhase 2
Pilot oral safety and efficacy of eucalypt sap resin for the management of recurrent vulvovaginal candidiasis (RVVC) and associated gastrointestinal symptoms: A comparative, 2-arm, double-blinded randomised study
Integria Healthcare (Australia) Pty Ltd.0 sites24 target enrollmentStarted: March 1, 2024Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Prevention
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- Female
Inclusion Criteria
- •Females with medically diagnosed recurrent vulvovaginal candidiasis (RVVC); and gastrointestinal symptoms of candida overgrowth for a minimum of four weeks
- •- No serious current illnesses or specific chronic illness (per exclusion criteria)
- •- Participants must be on contraception, and those participants who choose to use hormonal contraception should be on stable levels at least 6 weeks prior to and during the trial
- •- Any prescription medication use by participants (other than that listed in exclusion criteria) must be stable for six weeks or more prior to trial
- •- Ability and willingness to collect vaginal swabs; - Females with medically diagnosed recurrent vulvovaginal candidiasis (RVVC); and gastrointestinal symptoms of candida overgrowth for a minimum of four weeks
- •- No serious current illnesses or specific chronic illness (per exclusion criteria)
- •- Participants must be on contraception, and those participants who choose to use hormonal contraception should be on stable levels at least 6 weeks prior to and during the trial
- •- Any prescription medication use by participants (other than that listed in exclusion criteria) must be stable for six weeks or more prior to trial
- •- Ability and willingness to collect vaginal swabs
Exclusion Criteria
- •- Pregnant, planning pregnancy or breastfeeding
- •- Not willing to use contraception for the duration of the study
- •- Taking warfarin or any other anti-coagulant medication, diabetic medication, corticosteroids, antibiotics, or immunosuppressive medications/treatments
- •- Diagnosed with cancer (if active within last five years and excepting skin cancer)
- •- Individuals diagnosed with significant chronic illness including inflammatory bowel disease, liver disorders, kidney disease, autoimmune disorders, pelvic inflammatory disease, cystitis, sexually transmitted infections (STI), or any other medically diagnosed vulvovaginal conditions (excepting RVVC)
- •- Treatment of any vaginal infection, STI or urinary tract infection within the last six weeks including the use of vaginal douches, pessaries, probiotics (including vaginal and oral administration) for any reason
- •- Use of corticosteroids or oral antibiotics for any condition within the last four weeks
- •- Use of any antifungal treatments regularly for control of RVVC, including medications (i.e., Nystatin or fluconazole) or herbal treatment (i.e., Pau D’arco or horopito). Probiotics are permissible providing the use is regular for four weeks or more and ongoing
- •- Currently unwell with acute infection or fever or having Covid-19 within the last four weeks
- •- In poor general health as assessed by Study Investigators; - Pregnant, planning pregnancy or breastfeeding
- •- Not willing to use contraception for the duration of the study
- •- Taking warfarin or any other anti-coagulant medication, diabetic medication, corticosteroids, antibiotics, or immunosuppressive medications/treatments
- •- Diagnosed with cancer (if active within last five years and excepting skin cancer)
- •- Individuals diagnosed with significant chronic illness including inflammatory bowel disease, liver disorders, kidney disease, autoimmune disorders, pelvic inflammatory disease, cystitis, sexually transmitted infections (STI), or any other medically diagnosed vulvovaginal conditions (excepting RVVC)
- •- Treatment of any vaginal infection, STI or urinary tract infection within the last six weeks including the use of vaginal douches, pessaries, probiotics (including vaginal and oral administration) for any reason
- •- Use of corticosteroids or oral antibiotics for any condition within the last four weeks
- •- Use of any antifungal treatments regularly for control of RVVC, including medications (i.e., Nystatin or fluconazole) or herbal treatment (i.e., Pau D’arco or horopito). Probiotics are permissible providing the use is regular for four weeks or more and ongoing
- •- Currently unwell with acute infection or fever or having Covid-19 within the last four weeks
- •- In poor general health as assessed by Study Investigators
Investigators
Similar Trials
Completed
Phase 3
Evaluation of effects of eucalyptus tablets on the process of covid 19 diseaseCOVID-19 disease.COVID-19U07.1IRCT20200913048701N1Iran University of Medical Sciences50
Not yet recruiting
Phase 1
Topical use of Eucalypt sap resin for damaged skiACTRN12624000276550Integria Healthcare (Australia) Pty Ltd.60
Completed
Phase 1
Oral safety and tolerability of Eucalypt and Corymbia sap resins in healthy adults – A randomised controlled studyIrritable bowel syndrome - DAlternative and Complementary Medicine - Herbal remediesOral and Gastrointestinal - Normal oral and gastrointestinal development and functionACTRN12623000280606Integria Healthcare (Australia) Pty Ltd.42
Not yet recruiting
Phase 3
The efficacy of eucalyptus essence inhalation in hospitalized patients with COVID-19IRCT20201127049507N1Ghoum University of Medical Sciences40
Completed
Phase 4
The evaluation of the efficacy and safety of oral fingolimod in relapsing remitting multiple sclerosismultiple sclerosis.Disseminated Multiple SclerosisIRCT201406018323N10Vice-chancellor for research, Kermanshah University of Medical Sciences60